Guideline Summary for Tumor Mutational Burden (TMB) Testing and Pembrolizumab Eligibility

1. Testing Prioritization and Biomarker Hierarchy

• MSI‑H/dMMR testing should be performed first, because it provides a stronger predictive value for immunotherapy response than TMB alone. (National Comprehensive Cancer Network [NCCN]) 1
• PD‑L1 expression testing is recommended next, using tumor‑type‑specific thresholds (e.g., cervical cancer requires CPS ≥ 1). (NCCN) [1][2]
• Actionable driver‑mutation testing (EGFR, ALK, BRAF, NTRK, RET fusions) precedes TMB assessment, as targeted therapies may be available. (NCCN) [3][4]
• TMB testing is a last‑resort option and should only be considered when the above biomarkers are negative or have failed and no other satisfactory treatment options exist. (NCCN) 1

2. Tumor‑Specific Exceptions

• Colorectal cancer should not undergo TMB testing outside clinical trials; NCCN recommends against it because TMB‑high metastatic colorectal cancer shows low efficacy (≈ 11 % objective response rate, 31 % disease‑control rate). (NCCN) [4][3]5

3. Definition of TMB‑High and Testing Methodology

• FDA‑approved TMB‑high definition: ≥ 10 mutations per megabase (mut/Mb) measured by an FDA‑cleared assay. (U.S. Food and Drug Administration) [1][2]
• FoundationOne CDx is the FDA‑approved companion diagnostic for determining TMB‑high status for pembrolizumab eligibility; it uses a 324‑gene next‑generation sequencing panel covering the coding genome and has demonstrated good concordance with whole‑exome sequencing in retrospective validation. (FDA) [1][2]

Nuance on Cutoff Thresholds

• Higher TMB cutoffs may better predict response in certain contexts: the MyPathway trial showed an objective response rate of 38.1 % for patients with TMB ≥ 16 mut/Mb versus 2.1 % for those below this threshold. (NCCN) 1

4. Clinical Outcomes Associated with TMB‑High Status

• Pembrolizumab yields a 29 % objective response rate in TMB‑high (≥ 10 mut/Mb) tumors, compared with 6 % in non‑TMB‑high tumors, as observed in the KEYNOTE‑158 trial. Benefit was seen across multiple histologies, excluding colorectal cancer. (NCCN) [3][5]

5. Limitations, Pitfalls, and Biological Considerations

• TMB‑high status does not universally predict immunotherapy benefit; response varies by tumor type. (NCCN) 1
• Potential mechanisms of resistance despite high TMB include:
• Specimen requirements: adequate tumor tissue with sufficient tumor content is essential; for blood‑based TMB (bTMB), a circulating tumor DNA fraction ≥ 5 % is needed, while fractions < 1–2 % markedly reduce accuracy. (NCCN) [1][6]
• MSI‑H tumors frequently exhibit high TMB, but TMB‑high can occur independently; therefore, MSI/MMR testing should be prioritized because MSI‑H/dMMR tumors have superior immunotherapy responses compared with microsatellite‑stable/TMB‑high tumors. (NCCN) 1
• Age‑related confounder: in patients older than 50 years, low‑frequency mutations detected in cell‑free DNA may represent clonal hematopoiesis rather than tumor‑derived alterations, potentially inflating TMB estimates. (NCCN) 6

6. Practical Implementation Checklist

When TMB testing is indicated, use the FDA‑approved *FoundationOne CDx* assay to ensure results are interpretable for pembrolizumab eligibility. (FDA) [1][2]

Tumor Mutational Burden (TMB) and Its Clinical Significance

Definition and Measurement

• Tumor mutational burden (TMB) is a quantitative measure of the total number of somatic mutations present in a tumor genome, most commonly expressed as the number of mutations per megabase (mut/Mb) of DNA sequenced, as reported by eBioMedicine 7
• TMB values vary dramatically across cancer types, ranging from approximately 1 mutation/Mb in hematologic malignancies to over 10 mutations/Mb in solid tumors with hypermutant phenotypes, according to the Journal for ImmunoTherapy of Cancer 8, 9

Clinical Significance and FDA Approval

• The National Comprehensive Cancer Network (NCCN) notes that TMB has demonstrated predictive value for response to immune checkpoint inhibitors (particularly PD-1/PD-L1 inhibitors) across multiple cancer types, both retrospectively and prospectively, as reported by eBioMedicine 7
• Patients with TMB-H tumors treated with pembrolizumab achieved an objective response rate of 29% compared to 6% in non-TMB-H tumors, as seen in the phase II KEYNOTE-158 trial, according to the Journal of the National Comprehensive Cancer Network : JNCCN 10
• The relationship between TMB and immunotherapy response stems from the principle that higher mutational burden generates more tumor neoantigens (TNAs), which can be recognized by the immune system and enhance response to checkpoint blockade, as reported by the Journal for ImmunoTherapy of Cancer 8, 9

Testing Methodologies

• Blood-based TMB (bTMB) can be measured from circulating cell-free DNA, though it requires higher tumor content (typically ≥5% tumor fraction for accurate assessment) and has lower limits of detection compared to tissue-based testing, as reported by eBioMedicine 7

Important Clinical Limitations and Pitfalls

• In colorectal cancer specifically, the NCCN Panel does not currently recommend TMB biomarker testing outside of clinical trials, as limited data showed insufficient clinical activity (disease control rate 31%, objective response rate only 11% in TMB-H metastatic colorectal cancer treated with pembrolizumab), according to the Journal of the National Comprehensive Cancer Network : JNCCN 10
• Low circulating tumor DNA fractions significantly limit accuracy of TMB calling from blood samples, particularly when tumor content is below 1-2%, as reported by eBioMedicine 7

Relationship to Other Biomarkers

• The relationship between TMB, microsatellite instability (MSI), and PD-L1 expression is complex and tumor-type dependent, as reported by Annals of Oncology 11
• MSI-high tumors frequently demonstrate high TMB due to defective DNA mismatch repair, but TMB-high status can occur independently of MSI status, according to Annals of Oncology 11, 12
• NGS platforms that couple TMB analysis with MSI determination may represent a decisive tool for selecting patients for immunotherapy, particularly in cancers not belonging to the Lynch syndrome spectrum, as reported by Annals of Oncology 12